NCT04846634 - Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

February 29, 2028

Conditions

Resectable Locally Advanced Non-small Cell Lung Cancer

Interventions

DRUG

Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel

A cycle of treatment is defined as 21 days of once daily treatment.

DRUG

Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel

A cycle of treatment is defined as 21 days of once daily treatment.

DRUG

Penpulimab+Anlotinib

A cycle of treatment is defined as 21 days of once daily treatment.

Trial Locations (1)

The First Affiliated Hospital of Nanchang University, Nanchang